Current Report Filing (8-k)
October 15 2019 - 5:18PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 10, 2019
INTERPACE
DIAGNOSTICS GROUP, INC.
(Exact
name of Registrant as specified in its charter)
DELAWARE
|
|
0-24249
|
|
22-2919486
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
Morris
Corporate Center 1, Building C
300
Interpace Parkway,
Parsippany,
NJ 07054
(Address,
including zip code, of Principal Executive Offices)
(855)
776-6419
Registrant’s
telephone number, including area code:
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.01 par value per share
|
|
IDXG
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
October 10, 2019, Interpace Diagnostics Group, Inc. (the “Company”) held its Annual Meeting of Stockholders
(the “Annual Meeting”). The following proposals were voted on and approved by the Company’s stockholders
at the Annual Meeting with the stockholders having voted as set forth below:
Proposal
1:
|
To
elect one Class I member of the Board of Directors of the Company, who will serve for a term of three years and until such
director’s successor is elected and qualified.
|
|
|
For
|
|
Withhold
|
|
Broker Non-Vote
|
Stephen J. Sullivan
|
|
|
11,764,792
|
|
|
|
1,211,818
|
|
|
|
16,592,412
|
|
Proposal
2:
|
To
approve the Interpace Diagnostics Group, Inc. 2019 Equity Incentive Plan.
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
9,300,992
|
|
|
|
3,573,077
|
|
|
|
102,541
|
|
|
|
16,592,412
|
|
Proposal
3:
|
To
approve the Interpace Diagnostics Group, Inc. Employee Stock Purchase Plan.
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
10,208,651
|
|
|
|
2,719,748
|
|
|
|
48,211
|
|
|
|
16,592,412
|
|
Proposal
4:
|
To
approve, under applicable Nasdaq Listing Rules, issuances of shares of the Company’s Common Stock upon conversion of
the Company’s Preferred Stock in excess of 19.99% of the Company’s Common Stock outstanding prior to such issuances.
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
12,187,415
|
|
|
|
706,869
|
|
|
|
82,326
|
|
|
|
16,592,412
|
|
Proposal
5:
|
To
ratify the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2019.
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
29,181,857
|
|
|
|
164,008
|
|
|
|
123,156
|
|
|
|
-
|
|
Proposal
6:
|
To
adjourn the Annual Meeting.
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
28,171,373
|
|
|
|
821,741
|
|
|
|
219,182
|
|
|
|
356,726
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Interpace
Diagnostics Group, Inc.
|
|
|
|
/s/
Jack E. Stover
|
|
Jack
E. Stover
|
|
President
and Chief Executive Officer
|
Date:
October 15, 2019
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024